Tg Therapeutics Stock Current Valuation

TGTX Stock

USD 29.47 0.13 0.44%

Valuation analysis of TG Therapeutics helps investors to measure TG Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to rise to 88.43 in 2025. Enterprise Value Multiple is likely to rise to 88.43 in 2025. Fundamental drivers impacting TG Therapeutics' valuation include:

Price Book

23.7682

Enterprise Value

4.5 B

Enterprise Value Ebitda

769.4929

Price Sales

17.2484

Forward PE

20.8768

Undervalued

Today

29.47

Please note that TG Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of TG Therapeutics is based on 3 months time horizon. Increasing TG Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.

Buy or Sell Advice Valuation Matrix

Since TG Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of TGTX Stock. However, TG Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.

Historical

Market 29.47

Real 33.99

Target 40.88

Hype 29.59

Naive 27.32

The intrinsic value of TG Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence TG Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.

26.52

Downside

33.99

Real Value

Target Odds

Above Odds

Below Odds

37.28

Upside

Estimating the potential upside or downside of TG Therapeutics helps investors to forecast how TGTX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of TG Therapeutics more accurately as focusing exclusively on TG Therapeutics' fundamentals will not take into account other important factors:

Earnings

Estimates (0)

Low	Projected	High
0	0.09	0.15

Details

Hype

Prediction

Low	Estimated	High
26.30	29.59	32.88

Details

Naive

Forecast

Low	Next Value	High
24.03	27.32	30.61

Details

9 Analysts

Consensus

Low	Target Price	High
37.20	40.88	45.37

Details

TG Therapeutics Company Current Valuation Analysis

TG Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current TG Therapeutics Current Valuation

4.48 B

Most of TG Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TG Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

TGTX Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for TG Therapeutics is extremely important. It helps to project a fair market value of TGTX Stock properly, considering its historical fundamentals such as Current Valuation. Since TG Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of TG Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of TG Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Net Receivables	Accounts Payable	Common Stock	Property Plant Equipment	Short Term Investments	Long Term Debt	Short Term Debt	Current Deferred Revenue	Intangible Assets	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Treasury Stock	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.01	-0.63	-0.78	0.73	1.0	0.51	0.59	-0.05	0.75	0.65	0.6	0.75	-0.03	-0.37	0.81	0.51	0.53	0.87	-0.44	-0.44	-0.02	0.69	0.95	0.95	0.84
Total Stockholder Equity	0.01		-0.05	0.39	-0.18	0.06	0.25	0.03	-0.03	-0.32	0.15	-0.23	0.17	-0.27	0.09	0.01	0.01	-0.36	-0.26	0.24	0.14	-0.48	0.29	0.09	0.14	-0.26
Net Debt	-0.63	-0.05		0.16	-0.05	-0.63	0.31	-0.04	0.07	-0.47	0.15	0.21	-0.92	-0.01	0.17	-0.94	-0.04	0.22	-0.24	0.05	0.24	-0.15	-0.9	-0.72	-0.7	-0.21
Retained Earnings	-0.78	0.39	0.16		-0.85	-0.77	-0.62	-0.74	0.01	-0.76	-0.77	-0.88	-0.31	-0.04	0.38	-0.38	-0.54	-0.86	-0.97	0.5	0.47	0.02	-0.22	-0.65	-0.65	-0.94
Total Liab	0.73	-0.18	-0.05	-0.85		0.72	0.72	0.71	-0.24	0.59	0.85	0.83	0.17	0.12	-0.54	0.3	0.74	0.89	0.88	-0.33	-0.66	0.06	0.09	0.53	0.54	0.82
Total Current Assets	1.0	0.06	-0.63	-0.77	0.72		0.52	0.61	-0.05	0.74	0.67	0.59	0.76	-0.03	-0.36	0.8	0.5	0.51	0.86	-0.43	-0.43	-0.07	0.71	0.95	0.96	0.83
Net Receivables	0.51	0.25	0.31	-0.62	0.72	0.52		0.6	0.05	0.3	0.94	0.86	-0.05	-0.12	-0.17	-0.05	0.52	0.74	0.68	-0.43	-0.17	-0.31	-0.07	0.39	0.42	0.69
Accounts Payable	0.59	0.03	-0.04	-0.74	0.71	0.61	0.6		-0.14	0.5	0.8	0.67	0.29	0.14	-0.41	0.15	0.59	0.63	0.75	-0.16	-0.51	-0.52	0.27	0.41	0.45	0.66
Common Stock	-0.05	-0.03	0.07	0.01	-0.24	-0.05	0.05	-0.14		0.13	-0.04	0.05	0.02	-0.05	0.88	-0.07	-0.68	-0.1	-0.02	-0.67	0.71	-0.11	0.03	0.07	0.07	0.08
Property Plant Equipment	0.75	-0.32	-0.47	-0.76	0.59	0.74	0.3	0.5	0.13		0.44	0.54	0.47	0.07	-0.16	0.61	0.34	0.58	0.78	-0.32	-0.39	-0.01	0.39	0.69	0.67	0.7
Short Term Investments	0.65	0.15	0.15	-0.77	0.85	0.67	0.94	0.8	-0.04	0.44		0.89	0.13	-0.08	-0.32	0.11	0.63	0.82	0.82	-0.41	-0.36	-0.31	0.1	0.51	0.54	0.8
Long Term Debt	0.6	-0.23	0.21	-0.88	0.83	0.59	0.86	0.67	0.05	0.54	0.89		-0.01	-0.02	-0.27	0.06	0.55	0.92	0.88	-0.53	-0.29	-0.1	-0.09	0.44	0.45	0.87
Short Term Debt	0.75	0.17	-0.92	-0.31	0.17	0.76	-0.05	0.29	0.02	0.47	0.13	-0.01		-0.04	-0.14	0.9	0.1	-0.1	0.41	-0.24	-0.18	-0.11	0.99	0.84	0.83	0.4
Current Deferred Revenue	-0.03	-0.27	-0.01	-0.04	0.12	-0.03	-0.12	0.14	-0.05	0.07	-0.08	-0.02	-0.04		-0.09	-0.12	0.04	-0.05	-0.01	-0.08	-0.13	-0.17	-0.08	-0.15	-0.15	0.0
Intangible Assets	-0.37	0.09	0.17	0.38	-0.54	-0.36	-0.17	-0.41	0.88	-0.16	-0.32	-0.27	-0.14	-0.09		-0.24	-0.76	-0.39	-0.39	-0.36	0.81	-0.08	-0.1	-0.21	-0.22	-0.29
Net Tangible Assets	0.81	0.01	-0.94	-0.38	0.3	0.8	-0.05	0.15	-0.07	0.61	0.11	0.06	0.9	-0.12	-0.24		0.19	0.06	0.48	-0.21	-0.32	0.23	0.86	0.86	0.83	0.44
Good Will	0.51	0.01	-0.04	-0.54	0.74	0.5	0.52	0.59	-0.68	0.34	0.63	0.55	0.1	0.04	-0.76	0.19		0.61	0.59	0.23	-0.78	-0.05	0.07	0.34	0.35	0.53
Long Term Debt Total	0.53	-0.36	0.22	-0.86	0.89	0.51	0.74	0.63	-0.1	0.58	0.82	0.92	-0.1	-0.05	-0.39	0.06	0.61		0.84	-0.37	-0.47	0.11	-0.19	0.34	0.34	0.79
Capital Surpluse	0.87	-0.26	-0.24	-0.97	0.88	0.86	0.68	0.75	-0.02	0.78	0.82	0.88	0.41	-0.01	-0.39	0.48	0.59	0.84		-0.51	-0.47	-0.04	0.32	0.74	0.74	0.96
Deferred Long Term Liab	-0.44	0.24	0.05	0.5	-0.33	-0.43	-0.43	-0.16	-0.67	-0.32	-0.41	-0.53	-0.24	-0.08	-0.36	-0.21	0.23	-0.37	-0.51		-0.35	-0.07	-0.17	-0.47	-0.46	-0.62
Treasury Stock	-0.44	0.14	0.24	0.47	-0.66	-0.43	-0.17	-0.51	0.71	-0.39	-0.36	-0.29	-0.18	-0.13	0.81	-0.32	-0.78	-0.47	-0.47	-0.35		-0.13	-0.14	-0.26	-0.26	-0.34
Long Term Investments	-0.02	-0.48	-0.15	0.02	0.06	-0.07	-0.31	-0.52	-0.11	-0.01	-0.31	-0.1	-0.11	-0.17	-0.08	0.23	-0.05	0.11	-0.04	-0.07	-0.13		-0.16	-0.02	-0.07	-0.04
Short Long Term Debt	0.69	0.29	-0.9	-0.22	0.09	0.71	-0.07	0.27	0.03	0.39	0.1	-0.09	0.99	-0.08	-0.1	0.86	0.07	-0.19	0.32	-0.17	-0.14	-0.16		0.79	0.79	0.32
Net Invested Capital	0.95	0.09	-0.72	-0.65	0.53	0.95	0.39	0.41	0.07	0.69	0.51	0.44	0.84	-0.15	-0.21	0.86	0.34	0.34	0.74	-0.47	-0.26	-0.02	0.79		1.0	0.77
Net Working Capital	0.95	0.14	-0.7	-0.65	0.54	0.96	0.42	0.45	0.07	0.67	0.54	0.45	0.83	-0.15	-0.22	0.83	0.35	0.34	0.74	-0.46	-0.26	-0.07	0.79	1.0		0.77
Capital Stock	0.84	-0.26	-0.21	-0.94	0.82	0.83	0.69	0.66	0.08	0.7	0.8	0.87	0.4	0.0	-0.29	0.44	0.53	0.79	0.96	-0.62	-0.34	-0.04	0.32	0.77	0.77

Click cells to compare fundamentals

Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Competition

Predict TG Therapeutics

Enterprise Value Over Time

In accordance with the recently published financial statements, TG Therapeutics has a Current Valuation of 4.48 B. This is 68.81% lower than that of the Biotechnology sector and 3.56% lower than that of the Health Care industry. The current valuation for all United States stocks is 73.05% higher than that of the company.

TGTX Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TG Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TG Therapeutics could also be used in its relative valuation, which is a method of valuing TG Therapeutics by comparing valuation metrics of similar companies.

TG Therapeutics is currently under evaluation in current valuation category among its peers.

TG Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of TG Therapeutics from analyzing TG Therapeutics' financial statements. These drivers represent accounts that assess TG Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of TG Therapeutics' important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	980.9M	6.0B	1.6B	2.4B	2.2B	2.3B
Enterprise Value	909.1M	5.5B	1.6B	2.4B	2.2B	2.3B

TG Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, TG Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to TG Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

TGTX Fundamentals

	Return On Equity	-0.0805
	Return On Asset	-7.0E-4
	Profit Margin	(0.05) %
	Operating Margin	0.15 %
	Current Valuation	4.48 B
	Shares Outstanding	155.66 M
	Shares Owned By Insiders	9.81 %
	Shares Owned By Institutions	63.47 %
	Number Of Shares Shorted	26.88 M
	Price To Earning	(4.14) X
	Price To Book	23.77 X
	Price To Sales	17.25 X
	Revenue	233.66 M
	Gross Profit	233.85 M
	EBITDA	26.1 M
	Net Income	12.67 M
	Cash And Equivalents	195.71 M
	Cash Per Share	1.45 X
	Total Debt	110.8 M
	Debt To Equity	0.62 %
	Current Ratio	4.68 X
	Book Value Per Share	1.34 X
	Cash Flow From Operations	(31.41 M)
	Short Ratio	10.16 X
	Earnings Per Share	(0.10) X
	Target Price	40.33
	Number Of Employees	319
	Beta	2.26
	Market Capitalization	4.57 B
	Total Asset	329.59 M
	Retained Earnings	(1.51 B)
	Working Capital	264.22 M
	Current Asset	71.33 M
	Current Liabilities	16.88 M
	Net Asset	329.59 M

About TG Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze TG Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TG Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TG Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tg Therapeutics Stock Current Valuation

TG Therapeutics Company Current Valuation Analysis

Enterprise Value

Market Cap + Debt

-

Cash

Current TG Therapeutics Current Valuation

TGTX Current Valuation Driver Correlations

TGTX Current Valuation Peer Comparison

TG Therapeutics Current Valuation Drivers

TG Therapeutics ESG Sustainability

TGTX Fundamentals

About TG Therapeutics Fundamental Analysis

Also Currently Popular

Additional Tools for TGTX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY